OTCMKTS:SIGY Sigyn Therapeutics (SIGY) Stock Price, News & Analysis $3.53 0.00 (0.00%) As of 05/1/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsBuy This Stock About Sigyn Therapeutics Stock (OTCMKTS:SIGY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sigyn Therapeutics alerts:Sign Up Key Stats Today's Range$3.53▼$3.5350-Day Range$3.53▼$4.4952-Week Range$3.15▼$6.34VolumeN/AAverage Volume436 shsMarket Capitalization$5.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.Read More… Receive SIGY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sigyn Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SIGY Stock News HeadlinesSigyn Therapeutics Delays Yearly Report FilingMarch 31, 2025 | tipranks.comSigyn CEO Note: An Emerging New Industry, 15 Years in the MakingMarch 12, 2025 | finance.yahoo.comSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.May 2, 2025 | Stansberry Research (Ad)Sigyn CEO Note: Combating the Rising Threat of New Pandemic VirusesMarch 5, 2025 | finance.yahoo.comSigyn Therapeutics to be Featured in Fireside Chat With Zacks Healthcare AnalystFebruary 25, 2025 | finance.yahoo.comSigyn Therapeutics to Present at Tomorrow’s Small Cap Growth Virtual Investor ConferenceFebruary 5, 2025 | financialpost.comSigyn Therapeutics to Present at Tomorrow's Small Cap Growth Virtual Investor ConferenceFebruary 5, 2025 | globenewswire.comSigyn Therapeutics Announces the Appointment of Michael Ryan to Its Board of DirectorsJanuary 29, 2025 | finance.yahoo.comSee More Headlines SIGY Stock Analysis - Frequently Asked Questions How have SIGY shares performed this year? Sigyn Therapeutics' stock was trading at $3.15 at the start of the year. Since then, SIGY shares have increased by 12.1% and is now trading at $3.53. View the best growth stocks for 2025 here. How were Sigyn Therapeutics' earnings last quarter? Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) announced its quarterly earnings data on Tuesday, April, 15th. The company reported ($2.51) earnings per share for the quarter. How do I buy shares of Sigyn Therapeutics? Shares of SIGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sigyn Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sigyn Therapeutics investors own include Rocket Lab USA (RKLB), Archer Aviation (ACHR), Atlas Lithium (ATLX), OriginClear (OCLN), Boxed (BOXD), bluebird bio (BLUE) and BlackSky Technology (BKSY). Company Calendar Last Earnings4/15/2025Today5/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolOTCMKTS:SIGY CIK1642159 Webwww.sigyntherapeutics.com Phone(619) 353-0800FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,150,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-1,147.41% Debt Debt-to-Equity RatioN/A Current Ratio0.06 Quick Ratio0.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.80) per share Price / Book-1.26Miscellaneous Outstanding Shares1,605,000Free Float346,000Market Cap$5.67 million OptionableNot Optionable Beta-1.04 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:SIGY) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sigyn Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sigyn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.